Cargando…
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
SIMPLE SUMMARY: Surgery is the only potential cure for pancreatic ductal adenocarcinoma and should always be combined with adjuvant chemotherapy or other multimodal treatment. Besides the advances in such multimodal approaches, there has been substantial progress in surgical techniques to especially...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074119/ https://www.ncbi.nlm.nih.gov/pubmed/33923884 http://dx.doi.org/10.3390/cancers13081971 |
_version_ | 1783684282989936640 |
---|---|
author | Wei, Kongyuan Hackert, Thilo |
author_facet | Wei, Kongyuan Hackert, Thilo |
author_sort | Wei, Kongyuan |
collection | PubMed |
description | SIMPLE SUMMARY: Surgery is the only potential cure for pancreatic ductal adenocarcinoma and should always be combined with adjuvant chemotherapy or other multimodal treatment. Besides the advances in such multimodal approaches, there has been substantial progress in surgical techniques to especially address advanced resections. These techniques include specific operative steps, such as ‘artery first’ or ‘uncinate first’ approaches as well as techniques that allow safe vascular resection and reconstruction to achieve radical tumor removal. Most recently, also minimally-invasive and robotic approaches have been adopted for pancreatic cancer surgery; however, there is no high-level evidence on these evolving techniques especially with regards to long-term results compared to conventional surgical techniques. ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) represents an aggressive tumor of the digestive system with still low five-year survival of less than 10%. Although there are improvements for multimodal therapy of PDAC, surgery still remains the effective way to treat the disease. Combined with adjuvant and/or neoadjuvant treatment, pancreatic surgery is able to enhance the five-year survival up to around 20%. However, pancreatic resection is always associated with a high risk of complications and regarded as one of the most complex fields in abdominal surgery. This review gives a summary on the surgical treatment for PDAC based on the current literature with a special focus on resection techniques. |
format | Online Article Text |
id | pubmed-8074119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80741192021-04-27 Surgical Treatment of Pancreatic Ductal Adenocarcinoma Wei, Kongyuan Hackert, Thilo Cancers (Basel) Review SIMPLE SUMMARY: Surgery is the only potential cure for pancreatic ductal adenocarcinoma and should always be combined with adjuvant chemotherapy or other multimodal treatment. Besides the advances in such multimodal approaches, there has been substantial progress in surgical techniques to especially address advanced resections. These techniques include specific operative steps, such as ‘artery first’ or ‘uncinate first’ approaches as well as techniques that allow safe vascular resection and reconstruction to achieve radical tumor removal. Most recently, also minimally-invasive and robotic approaches have been adopted for pancreatic cancer surgery; however, there is no high-level evidence on these evolving techniques especially with regards to long-term results compared to conventional surgical techniques. ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) represents an aggressive tumor of the digestive system with still low five-year survival of less than 10%. Although there are improvements for multimodal therapy of PDAC, surgery still remains the effective way to treat the disease. Combined with adjuvant and/or neoadjuvant treatment, pancreatic surgery is able to enhance the five-year survival up to around 20%. However, pancreatic resection is always associated with a high risk of complications and regarded as one of the most complex fields in abdominal surgery. This review gives a summary on the surgical treatment for PDAC based on the current literature with a special focus on resection techniques. MDPI 2021-04-20 /pmc/articles/PMC8074119/ /pubmed/33923884 http://dx.doi.org/10.3390/cancers13081971 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wei, Kongyuan Hackert, Thilo Surgical Treatment of Pancreatic Ductal Adenocarcinoma |
title | Surgical Treatment of Pancreatic Ductal Adenocarcinoma |
title_full | Surgical Treatment of Pancreatic Ductal Adenocarcinoma |
title_fullStr | Surgical Treatment of Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Surgical Treatment of Pancreatic Ductal Adenocarcinoma |
title_short | Surgical Treatment of Pancreatic Ductal Adenocarcinoma |
title_sort | surgical treatment of pancreatic ductal adenocarcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074119/ https://www.ncbi.nlm.nih.gov/pubmed/33923884 http://dx.doi.org/10.3390/cancers13081971 |
work_keys_str_mv | AT weikongyuan surgicaltreatmentofpancreaticductaladenocarcinoma AT hackertthilo surgicaltreatmentofpancreaticductaladenocarcinoma |